康泰生物实控人前妻完成减持1103.2万股 套现1.92亿元

Core Viewpoint - The announcement from Kangtai Biological indicates the completion of a share reduction plan by its controlling shareholder's concerted actor, Yuan Liping, who has reduced her holdings significantly within the specified period [1][2]. Group 1: Share Reduction Details - Yuan Liping completed her share reduction plan by selling 11,031,942 shares from July 23, 2025, to August 6, 2025, at an average price of 17.44 yuan per share, totaling approximately 1.92 billion yuan [1][2]. - The remaining shares of 128,058 will not be further reduced [1]. - The reduction represents 0.99% of the company's total share capital [2]. Group 2: Background Information - Yuan Liping is a concerted actor of the company's controlling shareholder and actual controller, Du Weimin, and is a Canadian citizen [2]. - The company had previously announced a share reduction plan on July 1, 2025, allowing for a maximum reduction of 11,160,000 shares, which is 1.00% of the total share capital [3]. - Kangtai Biological raised 3 billion yuan through a non-public offering of shares in 2020, with the share price set at 110 yuan, which is currently below the market price [3]. Group 3: Fundraising Activities - In 2021, Kangtai Biological issued 20 million convertible bonds with a total fundraising amount of 2 billion yuan, netting approximately 1.99 billion yuan after expenses [4]. - Over the past five years, the company has raised a total of 5 billion yuan [4].